Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02211222
Title An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Recruitment Approved for marketing
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eisai Inc.
Indications

thyroid gland papillary carcinoma

thyroid gland follicular carcinoma

Therapies

Lenvatinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.